Research programme: wound healing agents - Helix BioMedix

Drug Profile

Research programme: wound healing agents - Helix BioMedix

Alternative Names: HB-107

Latest Information Update: 16 Dec 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Helix BioMedix
  • Class Peptides
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Burns; Wounds

Most Recent Events

  • 10 Oct 2005 This programme is still in active development
  • 14 Jul 2004 HB 107 is available for licensing (
  • 29 Jul 2003 Preclinical trials in Burns in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top